ReviewAngiogenesis2016
Plants and their active compounds: natural molecules to target angiogenesis.
Review in Angiogenesis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Angiogenesis Suppression via VEGF-VEGFR2 Inhibition and Stromal-Endothelial Crosstalk Disruption by Myrosinase-Activated Broccoli Extract.Molecules (Basel, Switzerland) · 2026Article
- Effect of Phenolic Compounds and Terpenes on the Flavour and Functionality of Plant-Based Foods.Nutrients · 2025Review
- Antioxidant Potential of Natural Extract ofLife (Basel, Switzerland) · 2025Article
- Eco-Friendly Algicidal Potential ofMicroorganisms · 2025Article
- In Vivo Assessment of Healing Potential of Ointments Containing Bee Products, Vegetal Extracts, and Polymers on Skin Lesions.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Exploring baicalein: A natural flavonoid for enhancing cancer prevention and treatment.Heliyon · 2024Review
- A 1, 4-benzoquinone derivative isolated fromSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- Anti(angiogenic) food components: can be a major source of bias in the investigation of angiogenesis inhibitors.Annals of translational medicine · 2023Review
- Antiangiogenic, Anti-Inflammatory and Antioxidant Properties ofMolecules (Basel, Switzerland) · 2023Article
- Jujuboside B suppresses angiogenesis and tumor growth via blocking VEGFR2 signaling pathway.Heliyon · 2023Article
- Inhibiting Angiogenesis by Anti-Cancer Saponins: From Phytochemistry to Cellular Signaling Pathways.Metabolites · 2023Review
- Preclinical Trial ofEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Gut Microbiota-Assisted Synthesis, Cellular Interactions and Synergistic Perspectives of Equol as a Potent Anticancer Isoflavone.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Natural compounds in the regulation of proteostatic pathways: An invincible artillery against stress, ageing, and diseases.Acta pharmaceutica Sinica. B · 2021Review
- VEGFR-2 kinase domain inhibition as a scaffold for anti-angiogenesis: Validation of the anti-angiogenic effects of carotenoids fromToxicology reports · 2021Article
- Unraveling the molecular mechanisms between inflammation and tumor angiogenesis.American journal of cancer research · 2021Review
- Raddeanin A inhibited epithelial-mesenchymal transition (EMT) and angiogenesis in glioblastoma by downregulating β-catenin expression.International journal of medical sciences · 2021Article
- Saikosaponin A, a Triterpene Saponin, Suppresses Angiogenesis and Tumor Growth by Blocking VEGFR2-Mediated Signaling Pathway.Frontiers in pharmacology · 2021Article
- Antiangiogenic Targets for Glioblastoma Therapy from a Pre-Clinical Approach, Using Nanoformulations.International journal of molecular sciences · 2020Review
- Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription.Theranostics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Angiogenesis, or new blood vessel formation, is an important process in the pathogenesis of several diseases and thus has been targeted for the prevention and treatment for many disorders. However, the anti-angiogenic agents that are currently in use are mainly synthetic compounds and humanized monoclonal antibodies, which are either expensive or toxic, thereby limiting their use in many patients. Therefore, it is necessary to identify less toxic, inexpensive, novel and effective anti-angiogenic molecules. Several studies have indicated that natural plant products can meet these criteria. In this review, we discuss the anti-angiogenic properties of natural compounds isolated from plants and the molecular mechanisms by which these molecules act. Finally, we summarize the advantages of using plant products as anti-angiogenic agents. Compared with currently available anti-angiogenic drugs, plant products may not only have similar therapeutic potential but are also inexpensive, less toxic, and easy to administer. However, novel and effective strategies are necessary to improve their bioavailability for clinical use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.